Navigation Links
NIAID media availability: Still searching for predictors of asthma attacks
Date:8/10/2009

A new study of persistent asthma in inner-city adolescents and young adults finds that an extensive set of clinical tests cannot successfully predict the future risk of asthma attacks in participants who both receive care based on current guidelines and adhere to treatment recommendations. This finding differs from previous reports suggesting that certain clinical findings and laboratory tests could help predict future asthma attacks. These earlier conclusions, however, were based on observations of patients with poorly controlled asthma who had not received care based on current guidelines.

The study was conducted by the Inner City Asthma Consortium (ICAC), a nationwide network of clinical researchers supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. ICAC member Rebecca Gruchalla, M.D., Ph.D., from the University of Texas Southwestern Medical Center in Dallas, led the study. Additional support for the research was provided by the NIH National Center for Research Resources.

The 46-week study included 546 adolescents and young adults (ages 12 to 20 years old) in 10 cities across the United States. At the start of the study, ICAC investigators gathered baseline data by conducting standard tests to assess asthma symptoms. An additional battery of tests evaluated lung inflammation, lung function and allergic status. The participants were then seen every 6 to 8 weeks at their respective ICAC centers, where they were they were treated for asthma based on NIH guidelines developed by the National Asthma Education and Prevention Program. During the study, the participants carefully adhered to their treatment regimens.

After the study was completed, the investigators analyzed the baseline measurements to determine if any of these assessments, alone or in combination, could predict future asthma symptoms or asthma attacks. The investigators observed no significant clinical correlations between these common laboratory test measurements and asthma exacerbations among the study participants.

This large, longitudinal study provides the most comprehensive analysis to date of a number of factors previously thought to be useful in predicting future asthma attacks. Based on a population of patients who followed their treatment and had well-controlled asthma, the results indicate clearly that there are no known common biological markers that can predict the course of the disease in such individuals. Further studies will be needed to identify possible predictive markers.


'/>"/>

Contact: Julie Wu
wujuli@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIAID funds $51M contract to create comprehensive model of immune responses
2. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
3. NIAID scientists identify new cellular receptor for HIV
4. NIAID to convene HIV Vaccine Summit
5. NIAID describes research priorities to fight drug-resistant tuberculosis
6. NIAID to advance B-cell approach to HIV vaccines
7. NIAID creates HIV vaccine discovery branch
8. NIAID awards contracts to search for protein markers of disease
9. NIAID media availability: Seizures following parasitic infection associated with brain swelling
10. NIAID honors AIDS activist Martin Delaney
11. NIAID and Chinese officials sign agreement to foster TB research in Chinas Henan province
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology: